FDA approves first immunotherapy regimen for breast cancer

The US Food and Drug Administration has granted its first approval to an immunotherapy regimen for breast cancer, the agency announced Friday.The trea...

Posted: Mar 8, 2019 7:12 PM
Updated: Mar 8, 2019 8:30 PM

The US Food and Drug Administration has granted its first approval to an immunotherapy regimen for breast cancer, the agency announced Friday.

The treatment received accelerated approval for triple-negative breast cancer that is locally advanced or metastatic, that cannot be surgically removed and whose cells include a protein called PD-L1. It comprises a combination of immunotherapy and chemotherapy: Tecentriq and Abraxane, respectively.

The FDA's decision comes after an October study published in the New England Journal of Medicine found that the therapy extended progression-free survival -- the amount of time in which a patient's cancer does not worsen. In the PD-L1 subgroup, the median progression-free survival for those receiving the combination treatment was 7.4 months, versus 4.8 months for those getting the chemotherapy with placebo, according to the FDA's announcement. The trial was funded by Genentech Inc., the maker of Tecentriq.

'This is the first time immunotherapy has worked in such a difficult to treat cancer, and is a huge step forward for these breast cancer patients,' lead study author Dr. Peter Schmid of Queen Mary University of London said in an October statement.

Dr. Otis Brawley, Bloomberg Distinguished Professor of oncology and epidemiology at Johns Hopkins University, said the FDA's decision to grant the treatment accelerated approval was 'the right thing to do' but cautioned that it's not the end of the story.

'The FDA has approved it based on progression-free survival with the hope that later on ... data will show that the treatment actually makes women live longer,' said Brawley, who was not involved in researching the treatment.

This FDA says it grants accelerated approvals to 'drugs that treat serious conditions, and that fill an unmet medical need' based on data that suggests, but may not directly measure, a clinical benefit. Drugmakers are still required to confirm that the drug is beneficial through later trials. If that happens, the drug may receive a traditional FDA approval. Otherwise, the agency may decide to pull the drug, as has happened in the past.

In this case, the drugmaker is expected to submit a final report detailing subsequent findings in September 2020, according to the approval letter from the FDA to Genentech.

Tecentriq, the brand name of the immunotherapy drug atezolizumab, was previously approved to treat other specific types of urinary and lung cancers.

Breast cancer patients on the newly approved therapy most commonly reported adverse reactions like hair loss, fatigue, nausea, headaches and decreased appetites, according to the FDA.

Dr. Larry Norton, director of the Evelyn H. Lauder Breast Center at Memorial Sloan Kettering Cancer Center, told CNN in October that scientists are learning 'so much and so rapidly about other ways to stimulate the immune system' that he predicts an 'explosion of well-designed studies that will push the agenda forward.'

Norton, who was not involved in the October study, said 'this is just the beginning of using immunotherapy for breast cancer.'

Triple-negative breast cancer

About 15% of breast cancers are triple-negative, according to the National Breast Cancer Foundation. The protein PD-L1 may be found in roughly a fifth of those cancers, research has shown.

Triple-negative breast cancer is most likely to affect Hispanic and African-American women and those with a BRCA1 gene mutation. It also tends to appear among women in their 40s and 50s.

'It is particularly tragic that those affected are often young,' Queen Mary University's Schmid said. 'We have desperately been looking for better treatment options.'

When breast cancer cells test negative for estrogen, progesterone or human epidermal growth factor 2 (HER2), it's called a triple-negative breast cancer. Therefore, it does not respond to any of the available hormonal cancer treatments.

It does respond to chemotherapy. However, cancer cells can quickly develop resistance to chemo drugs, allowing them to spread to other parts of the body, reducing survival rates.

How does it work?

Cancers have a way of eluding the body's immune system, which recognizes them as part of the body. That's where Tecentriq comes in: It's an antibody that attaches to the cancer cell and inactivates the PD-L1 protein, which is responsible for telling the immune system, 'don't attack me.'

Chemotherapy is also needed to 'rough up' the exterior of the cancer cell, Schmid explained. That allows the newly revved-up immune system to recognize and attack the invader.

'We are using chemotherapy to tear away the tumor's 'immune-protective cloak,' to expose it,' Schmid said, 'enabling people's own immune system to get at it.'

Norton said in October that 'I think the expectation is, this will change the standard of care.

'This is a real advance that is going to allow us to help more people.'

Indiana Coronavirus Cases

Data is updated nightly.

Cases: 1007681

Reported Deaths: 16470
CountyCasesDeaths
Marion1355212121
Lake664101166
Allen57993801
Hamilton46350465
St. Joseph44397615
Elkhart35949510
Vanderburgh32251480
Tippecanoe27933260
Johnson25107445
Hendricks23897359
Porter22929365
Madison18748409
Clark18557252
Vigo17479303
Monroe15263200
LaPorte15173250
Delaware15073263
Howard14748290
Kosciusko12348148
Hancock11728176
Bartholomew11639180
Warrick11292189
Floyd11108215
Wayne10986253
Grant10082220
Morgan9472176
Boone8926115
Dubois8271131
Henry8229152
Dearborn822393
Noble8031106
Marshall7939135
Cass7546121
Lawrence7457171
Shelby7189119
Jackson698289
Gibson6597115
Harrison649192
Knox6421106
Huntington6395100
DeKalb632399
Montgomery6264111
Miami593398
Putnam581278
Clinton576171
Whitley565755
Steuben562576
Wabash5332104
Jasper532079
Jefferson511297
Ripley500586
Adams482576
Daviess4677114
Scott438974
Greene425196
Wells424888
Clay423360
White418764
Decatur4169102
Fayette406587
Jennings387361
Posey376644
Washington359151
LaGrange359078
Randolph3452100
Spencer340243
Fountain335760
Sullivan329452
Starke317171
Owen314771
Fulton312667
Orange293664
Jay284645
Franklin265643
Perry265452
Rush262432
Carroll261934
Vermillion258654
Parke231426
Pike229243
Tipton228159
Blackford193142
Pulaski183757
Crawford159823
Newton158348
Benton150617
Brown146747
Martin138719
Switzerland135011
Warren121116
Union107016
Ohio84613
Unassigned0540

Ohio Coronavirus Cases

Data is updated nightly.

Cases: 1519304

Reported Deaths: 23955
CountyCasesDeaths
Franklin1642651696
Cuyahoga1464072459
Hamilton1053661431
Montgomery740661279
Summit617841111
Lucas56338917
Butler51580718
Stark466811064
Lorain35628585
Warren32836377
Mahoning30787693
Clermont28193330
Lake27063448
Delaware24208164
Licking23939294
Trumbull22885561
Fairfield22395247
Greene22350326
Medina22047313
Clark19863354
Richland18586292
Portage17978252
Wood17454224
Allen16001279
Miami15582306
Muskingum14831185
Columbiana14080274
Wayne13791271
Tuscarawas12724311
Marion11976180
Scioto11469162
Pickaway11373142
Erie10904184
Ross10586203
Lawrence9759153
Ashtabula9741204
Hancock9707155
Belmont9309209
Geauga8965157
Jefferson8567199
Huron8404143
Union819859
Washington8093144
Sandusky7827151
Athens777779
Knox7739144
Darke7689158
Seneca7372145
Ashland6967130
Auglaize679799
Shelby6530115
Brown636491
Crawford6274130
Defiance6218105
Mercer616493
Fulton602896
Highland600499
Madison594578
Guernsey593071
Logan591096
Clinton583793
Preble5720125
Putnam5335110
Williams529288
Perry518363
Champaign513173
Jackson510273
Ottawa488586
Coshocton484683
Morrow458858
Pike434367
Fayette429263
Hardin419480
Gallia418467
Adams417195
Van Wert372382
Henry365372
Holmes3642125
Hocking356782
Wyandot324662
Carroll302365
Paulding280347
Meigs265851
Monroe216254
Noble200347
Morgan194033
Harrison182146
Vinton166625
Unassigned05
Fort Wayne
Cloudy
44° wxIcon
Hi: 51° Lo: 37°
Feels Like: 44°
Angola
Partly Cloudy
32° wxIcon
Hi: 48° Lo: 34°
Feels Like: 32°
Huntington
Cloudy
44° wxIcon
Hi: 53° Lo: 41°
Feels Like: 44°
Decatur
Cloudy
44° wxIcon
Hi: 57° Lo: 43°
Feels Like: 44°
Van Wert
Cloudy
50° wxIcon
Hi: 55° Lo: 42°
Feels Like: 50°
Showers on tap for Sunday with the chance of a few thunderstorms.
WFFT Radar
WFFT Temperatures
WFFT National

Community Events